Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies

BACKGROUND: Autoimmune encephalitis (AE) with neuronal surface antibodies (NSAbs) presents pathogenesis mediated by B cell-secreting antibodies. Rituximab is a second-line choice for the treatment for AE with NSAbs, which can cause B cell depletion via targeting CD20. However, the optimal protocol a...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Ying, Zhao, Chao, Liu, Juntong, Li, Chuan, Yan, Qi, Li, Lin, Hao, Yunfeng, Yao, Dan, Si, Huaxing, Zhao, Yingjun, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587594/
https://www.ncbi.nlm.nih.gov/pubmed/36273158
http://dx.doi.org/10.1186/s12974-022-02622-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587594/
https://www.ncbi.nlm.nih.gov/pubmed/36273158
http://dx.doi.org/10.1186/s12974-022-02622-8

Ejemplares similares